Yeah, all that wondering gives me an uncomfortable feeling. Why is nobody knocking? And why does SPL seem so reluctant to complete any of the DEP Phase 2 trials? As seen in the annual report, SPL keeps recruiting more patients and expanding the scope of the trials, BUT without any explanation. We are left to wonder and speculate...
SPL Price at posting:
$1.18 Sentiment: Hold Disclosure: Held
